Pancreatic Myeloid Sarcoma

Cureus. 2020 Jun 5;12(6):e8462. doi: 10.7759/cureus.8462.

Abstract

Myeloid sarcoma is an isolated extramedullary tumor mass consisting of immature myeloid cells. It is characterized by highly variable outcomes and usually disrupts the normal architecture of the normal tissue in which it originates. It may occur de novo or be associated with other hematological malignancies. Clinical presentation of myeloid sarcomas can be highly variable based on the tumor site, size, and extent of tissue involvement. The diagnosis of myeloid sarcoma is challenging and requires a high index of suspicion. Tissue sampling followed by the use of auxiliary studies is essential for diagnosis. Moreover, bone marrow sampling is necessary to exclude morrow involvement. Currently, the recommended therapeutic regimens for myeloid sarcoma are similar to those for acute myeloid leukemia. Much work remains to be accomplished as myeloid sarcomas, if initially missed or misdiagnosed, have poor overall survival rates. Furthermore, prognostic factors for this malignancy remain poorly understood.

Keywords: acute myeloid leukemia; allogenic bone marrow transplant; chemotherapy; extramedullary leukemia; granulocytic sarcoma; myeloid sarcoma; pancreatic sarcoma.

Publication types

  • Case Reports